VIA
RIGL icon

Virtus Investment Advisers’s Rigel Pharmaceuticals RIGL Stock Holding History

Virtus Investment Advisers’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$181K Buy
6,686
+162
+2% +$5.44K 0.05% 430
2025
Q4 		$279K Buy
+6,524
New +$246K 0.08% 273

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtus Investment Advisers's RIGL Position: Q1 2026 in Review

Virtus Investment Advisers increased its Rigel Pharmaceuticals (RIGL) stake by 2.5% in Q1 2026, buying an estimated $5.44K and bringing the position to 6,686 shares worth $181K. The position accounts for 0.05% of the portfolio, ranked #430.

Virtus Investment Advisers first reported a position in RIGL in Q4 2025 and has held it in 2 quarters since. The position peaked at $279K in Q4 2025. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • Virtus Investment Advisers held 6,686 shares of Rigel Pharmaceuticals worth $181K as of Q1 2026.
  • Virtus Investment Advisers bought 162 Rigel Pharmaceuticals shares in Q1 2026, an estimated $5.44K.
  • Rigel Pharmaceuticals made up 0.05% of Virtus Investment Advisers's portfolio in Q1 2026, its #430 holding.
  • Virtus Investment Advisers first reported a position in Rigel Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Virtus Investment Advisers's Rigel Pharmaceuticals position peaked at $279K in Q4 2025.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Virtus Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.